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Introduction: As treatments for non–small-cell lung cancer 
(NSCLC) become personalized, cellular and molecular differentia-
tion of the tumor is becoming the standard of care. Our objective is 
to compare the yield of different diagnostic procedures for cellular 
differentiation of NSCLC and analysis of epidermal growth factor 
receptor (EGFR) mutation.
Methods: We evaluated all patients diagnosed with NSCLC from 
January 2004 to September 2010 at the Jewish General Hospital, 
Montreal. Diagnostic procedures included surgical biopsies, non-
surgical histologic biopsies (endobronchial and core needle), trans-
bronchial needle aspirate (TBNA) and transthoracic needle aspirate 
(TTNA), bronchoalveolar lavage (BAL), and pleural fluid samples.
Results: We included 702 subjects investigated for histopathologic 
differentiation of NSCLC. Of these, 269 were also investigated for 
EGFR mutation. Failure to ascertain the cellular subtype and EGFR 
mutation status was least likely with surgical specimens (0% and 
1.8%, respectively); followed by TTNA (14% and 10%, respec-
tively) and histologic biopsy (18% for both); and was frequent with 
TBNA (39% and 30%, respectively). Although BAL and pleural 
fluid specimens provided reasonable yield for cellular differentia-
tion (20 % and 11%, respectively), their results were not accurate in 
6% of their samples when compared with concurrent or subsequent 
surgical specimens (reference standard) performed in a subgroup 
of patients.
Conclusion: Radiologically guided TTNA and histologic biopsies 
provided high yield for both molecular and histologic analyses. 
The yield of unguided TBNA was relatively low. Further studies are 
needed to assess the adequacy of BAL and pleural fluid samples for 
EGFR mutation analysis and accurate characterization of cellular 
subtypes of NSCLC.
Key Words: Lung cancer, cellular differentiation, EGFR, proce-
dures, diagnosis
(J Thorac Oncol. 2014;9: 1120–1125)
Minimally invasive nonsurgical procedures have been successfully used to diagnose lung cancer;1–4 however, 
their utility for cellular differentiation and genetic profiling 
of tumor cells has not been established. As treatments for 
non–small-cell lung cancer (NSCLC) become increasingly 
personalized, especially for advanced diseases, the cellular 
and genetic differentiation of the tumor is becoming essen-
tial for the selection of appropriate treatment regimens.5,6 
The American Society of Clinical Oncology stated in 2011 
“to obtain tissue for more accurate histologic classiﬁcation or 
investigational purposes, update committee supports reason-
able efforts to obtain more tissue than that contained in routine 
cytology specimen.”7 This is sometimes challenging, particu-
larly when dealing with advanced disease in which invasive 
intervention is less feasible, despite the need for adequate tis-
sue sampling for histologic and molecular analyses.
Recent studies suggest that cytologic specimens, which 
are obtained using nonsurgical procedures, are sufficient for 
cellular differentiation and molecular analysis of NSCLC.8,9 
Different cytologic specimens, however, cannot be combined 
as one entity because the methods of sampling may have great 
impact on their diagnostic yield. Adequate number of cancer 
cells relative to normal cells in diagnostic samples is crucial 
to determine tumor-specific mutations.10 Therefore, advanced 
procedures that target lesions under radiology guidance and 
provide samples with high proportion of abnormal cells are 
expected to have better diagnostic yield than unguided proce-
dures. To our knowledge, no study has directly compared the 
utility of different nonsurgical procedures in obtaining accu-
rate cellular differentiation and genetic profile of NSCLC. Our 
objective is to determine and compare the yield of different 
diagnostic procedures for accurate cellular differentiation of 
NSCLC and analysis of epidermal growth factor receptor 
(EGFR) mutation.
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PATIENTS AND METHODS
Study Population
The study cohort consists of all patients diagnosed with 
NSCLC between January 2004 and September 2010 at the 
Jewish General Hospital (JGH), Montreal. Patients were eli-
gible if the diagnostic procedure and the histopathologic and 
molecular analyses were performed at the JGH.
Demographic data, diagnostic procedures, and disease 
status were obtained from the pulmonary oncology database at 
the JGH. Details about the histopathologic and molecular analy-
ses were obtained from the patients’ medical records. This study 
was approved by the Research Ethics Committee of the SMBD-
JGH and all study participants signed an informed consent form.
Diagnostic Procedures
The initial procedure for obtaining adequate tissue for 
diagnosis of NSCLC was considered the diagnostic procedure. 
Based on the method of obtaining the tissue samples, these diag-
nostic procedures were classified as surgical and nonsurgical 
procedures. The surgical procedures included primary and sec-
ondary tumor resections. The nonsurgical procedures included:
•  Histologic biopsy (i.e., procedures that provide tissue 
samples, including endobronchial biopsy and transtho-
racic core needle [16–18 gauge needle size]);
•  Bronchoalveolar lavage (BAL);
•  Pleural fluid;
•  Conventional transbronchial needle aspirate (TBNA; 22 
gauge needle size);
•  CT guided transthoracic needle aspirate (TTNA; 22 
gauge needle size).
Samples obtained by surgeries and nonsurgical biop-
sies (histologic biopsies) provided histologic (or tissue-based) 
specimens. BAL, pleural fluid, TBNA, and TTNA provided 
cytologic (or cellular-based) specimens.
Histopathologic and Molecular Analyses
Using the electronic database from the pathology 
department, all information regarding histological and cyto-
logical analysis was retrospectively gathered for each case, 
including immunocytochemical/immunohistochemical data 
whenever available. All cases were re-classified into four 
groups: adenocarcinoma, squamous cell carcinoma, NSCLC 
not otherwise specified (NOS), and others (large cell, neuro-
endocrine, sarcomatoid, and mixed types). NSCLC-NOS was 
defined when the analysis of histologic and/or cytological 
specimens show neither clear evidence of glandular or that of 
squamous differentiation, due to either the nature of the tumor 
(poor differentiation) or scarcity of tumor sampling. Poorly 
differentiated NSCLC was defined when the cellular subtype 
was not determined by nonsurgical specimens despite ade-
quate immunohistochemistry (IHC) staining. The diagnosis 
of large cell carcinoma was only accepted in resected tumor, 
that had undergone thorough histologic examination, with the 
aid of ancillary techniques (special stains and IHC) to exclude 
either squamous or adenocarcinoma differentiation.11
Fragment analysis on a DNA sequencer for exon 19 
and real-time polymerase chain reaction for exon 21 were 
performed in a proportion of samples with nonsquamous 
histology. All slides pertaining to cases where EGFR was 
ordered were reviewed by a pathologist. A new section from 
the selected paraffin block to be tested was taken, stained 
with H&E, and re-evaluated by the pathologist for documen-
tation of tumor viability, and evaluation of tumor percentage 
in relation to the nontumoral component. As per our own 
validation process, exon 19 and exon 21 analysis can be per-
formed successfully in samples with a minimum of 5% tumor 
and/or at least 100 tumor cells. We do not microdissect for 
enrichment, since most of our samples are either too small 
and because a significant percentage are aspiration biopsies, 
resulting in tumor cells being admixed with non-neoplastic 
ones. Moreover, during the validation process, we were unable 
to detect significant sensitivity differences between enriched 
and nonenriched samples. For cytology (aspiration biopsy 
samples), we have only validated our EGFR detection method 
for specimens that have been collected in cell blocks. In fact, 
in our hospital, aspiration biopsies are seldom prepared with 
smears; we have opted to give preference to preparation of 
cell blocks for most aspiration biopsies, using formalin solu-
tion at 10% as fixative, with aggregation of the cell pellet with 
Histogel after centrifugation. Unsatisfactory EGFR mutation 
analysis was defined in specimen with either insufficient num-
ber of cells, as determined by the pathologist, or failed assay, 
in which no results (either positive or negative) was obtained.
Statistical Analysis
Descriptive and regression analyses were performed to 
investigate potential confounding factors related to subjects’ 
demographic and clinical characteristics. The yield for histo-
logic and molecular differentiation of the different procedure 
groups was assessed by comparing the proportions of NSCLC-
NOS and unsatisfactory EGFR mutation analysis using χ2 test. 
In addition, univariate and multivariate logistic regression 
analyses were performed, and the results were expressed as 
odds ratios (OR) and 95% confidence intervals (CI). From a 
multicategory variable that contains the different nonsurgical 
specimens (histologic biopsy, BAL, pleural fluid, TBNA, and 
TTNA), the histologic biopsy category was used as a reference 
category to construct four dummy variables, each represent-
ing one of the other nonsurgical (cytologic) specimens. To deal 
with missing values, multiple imputation was performed using 
Bayesian statistic approach with noninformative prior values.
Sensitivity Analysis
To estimate the proportion of specimens with unde-
termined cellular subtype due to inadequate sampling, we 
repeated the comparative analysis after excluding specimens 
with poorly differentiated NSCLC (defined as undifferenti-
ated cellular subtype in nonsurgical specimens after adequate 
IHC staining).
Diagnostic Accuracy
In a subgroup of patients who underwent both surgical 
and nonsurgical procedures, the surgical procedure was used 
as a reference standard (standard procedure) to evaluate the 
accuracy of each corresponding nonsurgical procedure for 
1122 Copyright © 2014 by the International Association for the Study of Lung Cancer
Albanna et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 8, August 2014
determining the cellular subtypes (i.e., comparing the result 
from the nonsurgical procedure to the result from the stan-
dard surgical procedure done for the same patient). This was 
assessed by determining the sensitivity (number of cases 
correctly diagnosed using nonsurgical specimens/number of 
cases diagnosed using surgical specimens) and the proportion 
of incorrect diagnosis (number of cases with discordant diag-
nosis). When a diagnosis of large cell carcinoma, which can-
not be made by small biopsies as per our definition, was made 
by the surgical specimen, the expected (accurate) diagnosis by 
the corresponding nonsurgical specimen was NSCLC-NOS. 
All analyses were conducted using STATA (version 12) and 
WinBUGS14 softwares.
RESULTS
Between January 2004 and September 2010, a total of 
912 subjects were identified; of whom, 702 were included in 
the analysis (Fig. 1). All 702 subjects had a confirmed tissue 
diagnosis of NSCLC. Diagnostic tissue specimens from all 
702 subjects were analyzed for cellular subtype of NSCLC. A 
subgroup of 269 subjects was also assessed for EGFR muta-
tion status. Table 1 shows patient demographics and disease 
characteristics.
The proportions of adenocarcinoma and squamous cell 
carcinoma were comparable between the surgical and nonsur-
gical specimens. However, the nonsurgical specimens yielded 
a higher proportion of NSCLC-NOS (25% vs. 0%, p < 0.001; 
Fig. 2).
Among the nonsurgical specimens, the proportion 
of NSCLC-NOS was 18% (95% CI, 12–25%) in histologic 
biopsies, 20% (95% CI, 9–35%) in BAL samples, 11% (95% 
CI, 4–23%) in pleural fluid samples, 39% (95% CI, 32–46%) 
in TBNA, and 14% (95% CI, 7–24%) in TTNA (p < 0.001). 
Comparing the different cytologic specimens to the histologic 
biopsy, the yield of conventional TBNA for determining the 
cellular subtype of NSCLC was significantly worse (adjusted 
OR, 3.4; 95% CI, 1.9–5.7). Otherwise, the yield of BAL 
(adjusted OR, 1.1; 95% CI, 0.4–2.5), pleural fluid (adjusted 
OR, 0.6; 95% CI, 0.2–1.6), and TTNA (adjusted OR, 0.7; 95% 
CI, 0.3–1.4) were not significantly different (Table 2).
After excluding samples with poorly differentiated 
NSCLC (defined as undifferentiated cellular subtype in 
nonsurgical specimens after adequate IHC staining), the 
remaining nonsurgical specimens with undetermined cellular 
subtypes were 2% (95% CI, 0.4–5.7%) in histologic biopsies, 
17% (95% CI, 7–32%) in BAL, 6% (95% CI, 1.3–17.5%) 
in pleural fluid, 15% (95% CI, 10–21%) in TBNA, and 8% 
(3–17%) in TTNA (p = 0.001).
There was a subgroup of 93 subjects who underwent 
both surgical and nonsurgical procedures. The sensitivity of 
the nonsurgical procedures in this subgroup of patients was 
88% (95% CI, 70–98%) for histologic biopsies, 81% (95% 
CI, 54–96%) for BAL, 76% (95% CI, 50–93%) for pleural 
fluid, and 71% (95% CI, 53–85%) for fine needle aspirates 
(TBNA and TTNA combined). All diagnoses from nonsurgi-
cal specimens were correct (concordant to surgical diagnosis) 
except for one (6% [95% CI, 0.2–30%]) from BAL and one 
(6% [95% CI, 0.1–29%) from pleural fluid samples.
The diagnostic yield for determination of the EGFR 
status varied substantially between the different procedures. 
The proportion of unsatisfactory results (defined in the meth-
ods section) was 1.8% in surgical and 23.6% in nonsurgical 
specimens (p < 0.001). Among the nonsurgical specimens, 
this proportion was 18% (95% CI, 8.6–31.4) in histologic 
biopsies, 30% (95% CI, 18.5–42.6%) in TBNA, and 10% 
(95% CI, 2.2–27.4%) in TTNA. Because of the small num-
ber of subjects, we could not adjust for multiple covariates; 
however, age-adjusted estimates did not change the trend of 
the diagnostic yields of the different diagnostic procedures 
(Table 3). The proportion of positive EGFR mutation result 
was 15% (95% CI, 8.6–22%) in surgical specimen, 20% (95% 
CI, 6.9–32%) in histologic biopsy, 23% (95% CI, 10–36%) in 
TBNA, and 31% (95% CI, 12–50%) in TTNA. The number of 
BAL and pleural fluid samples analyzed for EGFR mutation 
was too small (nine and eight samples, respectively) to pro-
vide accurate estimates.
FIGURE 1.  Population selection. BAL, bronchoal-
veolar lavage; TBNA, conventional transbronchial 
needle aspirate; TTNA, CT guided transthoracic 
needle aspirate. *Includes endobronchial and core 
needle biopsies.
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DISCUSSION
In our population, we compared the yield of different 
diagnostic nonsurgical procedures for accurate cellular differ-
entiation and EGFR mutation analysis. Radiologically guided 
TTNA and histologic biopsies (i.e., endobronchial and trans-
thoracic core biopsies) provided relatively high yield for both 
cellular and molecular characterization of NSCLC. The yield 
from nonguided (conventional) TBNA was relatively low.
When compared with concurrent or subsequent surgi-
cal procedures, all nonsurgical procedures provided reason-
able sensitivity and accurate histopathologic analysis results 
except BAL and pleural fluid samples which provided incor-
rect results in 6% of samples.
Many studies have assessed the performance charac-
teristics of different diagnostic modalities for lung cancer 
diagnosis in general. Comparison between these modalities, 
however, was mainly done across studies, using meta-analysis 
methods, despite significant heterogeneity of results.12 Some 
studies have assessed the adequacy of nonsurgical samples 
to determine both cellular subtype and genetic mutation sta-
tus of NSCLC. Similar to our finding, the yield of TTNA in 
one study was high (over 90%) for both cellular differentia-
tion and EGFR mutation analysis.9 In another study, the cel-
lular subtype of NSCLC was determined in 85% of cytology 
specimens that included both TBNA and TTNA.8 The yield 
of endobronchial ultrasound guided TBNA (EBUS-TBNA) 
for EGFR mutation analysis varied between studies―ranging 
from 72%13 to 90%.14 Most comparative studies15–17 assessed 
the difference between cytologic specimens in general and 
histologic (tissue) specimens, although, to our opinion, the 
sampling technique of cytologic specimens may have great 
impact on the yield for cellular and molecular analyses. Many 
studies conclude that cytologic specimens provide high accu-
racy for cellular and molecular analyses. The majority of these 
studies, however, included either small number of subjects16 or 
a selected sample of specimens, most of which are radiologi-
cally guided,9 which may not be generalizable to all cytologic 
specimens performed in clinical practice. Based on a consen-
sus agreement at the International Association for the Study 
of Lung Cancer meeting, “cytology samples may be suitable 
for analysis but further research is needed to fully understand 
the clinical reliability of mutational data obtained from these 
samples.”10 To our knowledge, our study is the first study that 
compared the yield of different diagnostic procedures per-
formed in the usual clinical practice for cellular and molecular 
differentiation of NSCLC.
One limitation of this study is that a reference sam-
ple (surgical biopsy) was not available for all the patients. 
However, due to the fact that the majority of lung cancer 
patients are diagnosed in advanced stage, it is difficult to 
achieve comparable sample size of subjects who under-
went both surgical and each type of nonsurgical procedures. 
In addition, limiting the study to subjects who underwent 
TABLE 1.  Demographic and Disease Characteristics among Subjects Who Underwent Different Diagnostic Procedures
Surgery Histologic biopsya BAL Pleural fluid TBNA TTNA
No. = 199 No. = 150 No. = 41 No. = 47 No. = 191 No. = 74
Subject characteristics
Age, mean (SD) 66 (10.3) 68 (11.8) 70 (11.3) 72 (11.5) 69 (10.6) 72 (9.3)
Male gender, No. (%) 109 (54.8) 84 (56.0) 22 (53.7) 26 (56.5) 103 (54.5) 40 (54.1)
Smoking (ever), No. (%) 168 (85.7) 124 (87.3) 30 (79.0) 33 (75.0) 167 (89.3) 63 (85.1)
Performance status,b No. (%)
0–1 165 (82.9) 100 (67.6) 27 (65.9) 32 (68.1) 144 (75.8) 55 (75.3)
2–4 34 (17.1) 48 (32.4) 14 (34.2) 15 (31.9) 46 (24.2) 18 (24.7)
Tumor characteristics
Cancer stage No. (%)
I-II 115 (57.8) 13 (8.8) 11 (26.8) 4 (8.5) 19 (10.0) 18 (24.3)
III-IV 84 (42.2) 135 (91.2) 30 (73.2) 43 (91.5) 171 (90.0) 56 (75.7)
Tumor size (cm),c mean (SD) 3.4 (2.0) 5 (2.5) 4.8 (1.9) 3.8 (2.0) 4.7 (2.2) 4.4 (2.3)
aIncludes endobronchial and transthoracic core biopsies.
bECOG performance status scale.
cSize of the primary tumor.
BAL, bronchoalveolar lavage; TBNA, transbronchial needle aspirate; TTNA, transthoracic needle aspirate; SD, standard deviation.
FIGURE 2.  Proportions of cellular subtypes determined in 
surgical and nonsurgical specimens. NSCLC-NOS, non–small-
cell lung cancer not otherwise specified.
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surgery may not be generalizable to nonsurgical candidates 
who may also benefit from targeted therapies. Alternatively, 
we compared the yields across subjects and adjusted for 
potential confounding factors; however, residual confound-
ing by unmeasured factors is a possibility. To validate our 
results, we also analyzed the yield of nonsurgical procedures 
through direct comparison to the reference surgical proce-
dure in a subgroup of patients who underwent both proce-
dures. Although IHC staining has been done routinely in 
our center to characterize the cellular subtype of NSCLC, 
it may have not been performed during the work-up of 
some samples analyzed earlier before cellular differentia-
tion of NSCLC became a standard of care. This, however, is 
expected to similarly reduce the sensitivity of different non-
surgical specimens without significantly affecting the com-
parative inferences. We also did not have adequate number 
of samples to accurately estimate the yield of BAL and pleu-
ral fluid sampling procedures for EGFR mutation analysis. 
Another consideration to be discussed is that the denomina-
tor in our analysis did not include all subjects who under-
went the procedures, but only those diagnosed with NSCLC. 
However, IHC staining and EGFR mutation analyses are 
considered only when cancer cells are identified. Therefore, 
similar to other studies that assessed the utility for histo-
pathologic and molecular differentiation of NSCLC,8,9,13 we 
limited the denominator to subjects who were considered for 
the same diagnostic evaluation.
Despite these limitations, this study has a number of 
strengths. To our knowledge, this study constitutes the largest 
cohort of patients with NSCLC who were assessed to deter-
mine the sampling utilities for histologic and molecular dif-
ferentiation of the tumor. Unlike other studies that handled 
different cytologic specimens as one entity, we assessed them 
separately, based on the sampling procedure (BAL, pleural 
fluid, TBNA, and TTNA), and identified important differences 
between their utilities. Finally, all of the procedures were 
performed, and their samples were analyzed, in one institu-
tion, which reduced potential variability related to differences 
in procedure equipments and laboratory resources, thereby 
allowing for equitable comparison.
This study suggests that the yield of cytologic speci-
mens for cellular and molecular differentiation of NSCLC 
varies according to the performed procedure. Unlike other 
cytologic specimens, TTNA provided high yield, which was 
equivalent to the yield of nonsurgical histologic biopsy speci-
mens. This can be explained by the anticipated higher number 
of cancer cells in proportion to normal cells when the sam-
ples are obtained through direct or radiologic visualization of 
the tumor. Correspondingly, EBUS-TBNA may provide high 
yield; however, this requires direct comparison to other cyto-
logic specimens in further studies. Our study also suggests 
that BAL and pleural fluid specimens may occasionally pro-
vide incorrect cellular classification of NSCLC. These find-
ings can have important clinical implications for selecting the 
diagnostic modality that will likely provide enough informa-
tion to appropriately treat lung cancer patients.
We conclude from our study that the adequacy for cel-
lular differentiation of NSCLC and EGFR mutation analysis 
depends not only on the type of specimen (i.e., histologic ver-
sus cytologic), but also on the procedure used to obtain this 
specimen. Further studies are required to assess the adequacy 
of BAL and pleural fluid samples for determining EGFR 
mutation status and accurately differentiating the cellular sub-
type of NSCLC.
TABLE 2.  Odds Ratios (OR) of Having NSCLC-NOS, Comparing Different Nonsurgical Procedures
Diagnostic Procedure
NSCLC-NOS
Proportion (95% CI) Crude OR (95% CI) Adjusted OR (95% CI)a
Histologic biopsyb (No. 150) 18% (12.2–25.1%) 1 (Ref.) 1 (Ref.)
BAL (No. 41) 19.5% (8.8–34.9%) 1.1 (0.46–2.66) 1.1 (0.37–2.53)
Pleural fluid (No. 47) 10.6% (3.5–23.1%) 0.54 (0.2–1.5) 0.64 (0.17–1.57)
TBNA (No. 191) 38.7% (31.8–46%) 2.9 (1.7–4.8) 3.41 (1.9–5.7)
TTNA (No. 74) 13.5% (6.7–23.5%) 0.71 (0.32–1.56) 0.68 (0.26–1.44)
aAdjusted for age, sex, smoking history, primary tumor size, performance status, and cancer stage
bIncludes endobronchial and transthoracic core biopsies. Missing values were treated with multiple imputation, using Bayesian approach with noninformative prior values.
NSCLC-NOS, non–small-cell lung cancer not otherwise specified; BAL, bronchoalveolar lavage; TBNA, conventional transbronchial needle aspirate; CI, confidence interval; 
TTNA, CT guided transthoracic needle aspirate.
TABLE 3.  Odds Ratios (OR) of Having Unsatisfactory EGFR Mutation Status, Comparing Different Nonsurgical Procedures
Diagnostic Procedure
Unsatisfactory EGFR Mutation Analysis
Proportion (95% CI) Crude OR (95% CI) Adjusted OR (95% CI)a
Histologic biopsyb (No. 50) 18% (8.6–31.4) 1 (Ref.) 1 (Ref.)
TBNA (No. 61) 29.5% (18.5–42.6) 1.9 (0.77–4.7) 2 (0.8–5.3)
TTNA (No. 29) 10.3% (2.2–27.4) 0.5 (0.13–2.1) 0.5 (0.12–2.1)
Estimates for bronchoalveolar lavage and the pleural fluid samples were excluded because of small number of subjects (nine and eight, respectively).
aAdjusted only for age, no enough power to adjust for other covariates.
bIncludes endobronchial and transthoracic core biopsies.
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